Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Pancreatic
Advertisement
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Dr. Strosberg focuses on how previous exposure to alkylating agents can influence tumor biology or immune response.
Dr. Pant shared updates on a phase 1b dose escalation trial of gemcitabine, nab-paclitaxel, and lixumistat.
Dr. Shirakawa highlighted the results of the NAPOLEON-2 trial, including how RWD compare to clinical trial findings.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.